ZA200202757B - Compound with growth hormone releasing properties. - Google Patents

Compound with growth hormone releasing properties.

Info

Publication number
ZA200202757B
ZA200202757B ZA200202757A ZA200202757A ZA200202757B ZA 200202757 B ZA200202757 B ZA 200202757B ZA 200202757 A ZA200202757 A ZA 200202757A ZA 200202757 A ZA200202757 A ZA 200202757A ZA 200202757 B ZA200202757 B ZA 200202757B
Authority
ZA
South Africa
Prior art keywords
growth hormone
compound
hormone releasing
releasing properties
trimethylhydrazinocarbonyl
Prior art date
Application number
ZA200202757A
Other languages
English (en)
Inventor
Michael Ankersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of ZA200202757B publication Critical patent/ZA200202757B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Anesthesiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
ZA200202757A 1999-11-10 2002-04-09 Compound with growth hormone releasing properties. ZA200202757B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199901618 1999-11-10
US16710199P 1999-11-23 1999-11-23
PCT/DK2000/000624 WO2001034593A1 (en) 1999-11-10 2000-11-10 Compound with growth hormone releasing properties

Publications (1)

Publication Number Publication Date
ZA200202757B true ZA200202757B (en) 2003-02-26

Family

ID=26065963

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200202757A ZA200202757B (en) 1999-11-10 2002-04-09 Compound with growth hormone releasing properties.

Country Status (23)

Country Link
US (1) US6576648B2 (es)
EP (1) EP1230236B1 (es)
JP (2) JP2003527338A (es)
KR (1) KR100907637B1 (es)
CN (1) CN1198818C (es)
AT (1) ATE280168T1 (es)
AU (1) AU782260B2 (es)
BR (1) BR0015407A (es)
CA (1) CA2387095C (es)
CZ (1) CZ301078B6 (es)
DE (1) DE60015173T2 (es)
DK (1) DK1230236T3 (es)
ES (1) ES2231279T3 (es)
HU (1) HU229445B1 (es)
IL (1) IL149049A0 (es)
MX (1) MXPA02004656A (es)
NO (1) NO323910B1 (es)
PL (1) PL199989B1 (es)
PT (1) PT1230236E (es)
RU (1) RU2272034C2 (es)
UA (1) UA73530C2 (es)
WO (1) WO2001034593A1 (es)
ZA (1) ZA200202757B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261201A1 (en) * 2004-03-30 2005-11-24 Rejuvenon Corporation Method of reducing C-reactive protein using growth hormone secretagogues
CN1976921B (zh) 2004-06-29 2013-08-21 蓝宝石治疗公司 (3r)-1-(2-甲基丙氨酰-d-色氨酰)-3-(苯甲基)-3-哌啶羧酸1,2,2-三甲基酰肼的晶形
AU2005272074B2 (en) * 2004-06-29 2011-11-24 Albany Molecular Research, Inc. Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
US20130281701A1 (en) * 2004-06-29 2013-10-24 Helsinn Therapeutics (U.S.), Inc. Crystal forms of anamorelin
WO2006020930A2 (en) 2004-08-12 2006-02-23 Sapphire Therapeutics, Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
US8039456B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
KR20090042779A (ko) * 2006-06-30 2009-04-30 쉐링 코포레이션 Ｐ53 활성을 증가시키는 치환된 피페리딘 및 이의 사용
WO2008100448A2 (en) 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
US8664267B2 (en) * 2007-04-12 2014-03-04 Academic Pharmaceuticals Incorporated Parenteral solution containing amiodarone in NNDMA (N,N,-Dimethylacetamide)
ES2464342T3 (es) 2008-02-08 2014-06-02 Zeria Pharmaceutical Co., Ltd. Derivado de 3,8-diaminotetrahidroquinolina
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
BR112015009107A2 (pt) 2012-10-24 2017-11-14 Daiichi Sankyo Co Ltd agente terapêutico para esclerose lateral amiotrófica, uso de um agonista do receptor do secretagogo do hormônio do crescimento ou um sal farmaceuticamente aceitável do mesmo, e, agonista do receptor do secretagogo do hormônio do crescimento ou sal farmaceuticamente aceitável do mesmo
CN107001323A (zh) * 2015-10-20 2017-08-01 江苏恒瑞医药股份有限公司 一种阿拉莫林的结晶形式及其制备方法
CN106187865A (zh) * 2016-07-08 2016-12-07 武汉工程大学 (r)‑1‑叔丁氧羰基‑3‑苄基‑3‑甲酸哌啶的合成及手性拆分方法
CN108129357B (zh) * 2016-12-01 2021-12-21 上海医药工业研究院 阿拉莫林中间体的制备方法
CN108239141A (zh) * 2016-12-23 2018-07-03 江苏先声药业有限公司 一种阿拉莫林的制备方法
JP2022546162A (ja) * 2019-08-30 2022-11-04 ヘルシン ヘルスケア ソシエテ アノニム 安定性が改善されたアナモレリン錠剤の製造方法
CN114805305B (zh) * 2022-04-20 2024-04-26 成都诺和晟泰生物科技有限公司 一种化合物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839344A (en) 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
DE68922602T2 (de) 1988-01-28 1995-12-07 Polygen Holding Corp Polypeptide mit hormonwachstumsbefreiender wirkung.
WO1989010933A1 (en) 1988-05-11 1989-11-16 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
IT1240643B (it) 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
IL98910A0 (en) 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
AU1172995A (en) * 1993-11-09 1995-05-29 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
AU684878B2 (en) 1993-11-24 1998-01-08 Merck & Co., Inc. Compounds and the use thereof to promote the release of growth hormone(s)
US5721250A (en) 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
AU3434697A (en) * 1996-07-22 1998-02-10 Novo Nordisk A/S Compounds with growth hormone releasing properties
EP1506969B1 (en) * 1998-01-16 2010-06-09 Helsinn Therapeutics (U.S.), Inc. Compounds with growth hormone releasing properties
PL194560B1 (pl) * 1998-05-11 2007-06-29 Novo Nordisk As Związki o właściwościach uwalniania hormonu wzrostu, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie
US6303620B1 (en) * 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
US20010020012A1 (en) * 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake

Also Published As

Publication number Publication date
WO2001034593A1 (en) 2001-05-17
AU1269401A (en) 2001-06-06
DE60015173D1 (de) 2004-11-25
MXPA02004656A (es) 2002-09-02
JP5053960B2 (ja) 2012-10-24
AU782260B2 (en) 2005-07-14
KR20020059694A (ko) 2002-07-13
DK1230236T3 (da) 2005-02-21
HU229445B1 (en) 2013-12-30
CN1198818C (zh) 2005-04-27
CZ20021587A3 (cs) 2002-09-11
NO323910B1 (no) 2007-07-16
PL199989B1 (pl) 2008-11-28
ATE280168T1 (de) 2004-11-15
EP1230236A1 (en) 2002-08-14
US6576648B2 (en) 2003-06-10
IL149049A0 (en) 2002-11-10
CA2387095A1 (en) 2001-05-17
UA73530C2 (uk) 2005-08-15
JP2009062369A (ja) 2009-03-26
NO20022200L (no) 2002-05-08
KR100907637B1 (ko) 2009-07-14
CZ301078B6 (cs) 2009-10-29
DE60015173T2 (de) 2005-12-08
HUP0203844A2 (hu) 2003-03-28
US20010041720A1 (en) 2001-11-15
CN1420878A (zh) 2003-05-28
ES2231279T3 (es) 2005-05-16
PT1230236E (pt) 2005-03-31
JP2003527338A (ja) 2003-09-16
CA2387095C (en) 2011-01-11
NO20022200D0 (no) 2002-05-08
EP1230236B1 (en) 2004-10-20
PL356993A1 (en) 2004-07-12
HUP0203844A3 (en) 2004-07-28
RU2272034C2 (ru) 2006-03-20
BR0015407A (pt) 2002-07-02

Similar Documents

Publication Publication Date Title
HU229445B1 (en) Compound with growth hormone releasing properties
JO2371B1 (en) 4-phenyl-pyridine derivatives
TW200642685A (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
GEP20064005B (en) Use of novel benzoimidazole derivatives as antiproliferative agents
BG106586A (en) Pyrazolopyramidines as therapeutic agents
CA2392973A1 (en) Benzoimidazole derivatives useful as antiproliferative agents
HK1095139A1 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
IL172834A0 (en) Pyrimidine-,2,4-dione derivatives and pharmaceutical compositions containing the same
CA2534428A1 (en) Melanin concentrating hormone receptor antagonists
MXPA03008215A (es) Inhibidores de integrina alfa v beta 6.
SE9903997D0 (sv) New compounds
DK1077941T3 (da) Forbindelser med væksthormonfrigörende egenskaber
IL145684A0 (en) Treatment of pulmonary hypertension
AP2002002697A0 (en) Biciclic cyclohexylamines and their use as NMDA receptor antagonists.
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
MY122477A (en) Sertraline oral concentrate
PL341707A1 (en) Compounds exibiting growth hormone releasing properties
YU46302A (sh) Supstituisani piroli
HUP0104820A3 (en) Substituted benzimidazoles, production and use thereof as agents for combating parasitic protozoas
NO20012169D0 (no) Forbindelser med veksthormonfrigjörende egenskaper